We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the airwaves by Motley Fool analyst David Meier. David, thanks for joining me today.

Moderna MRNA announced that the U.S. government, through the Biomedical Advanced Research and Development Authority (“BARDA”) ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.

Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance.

The announcement comes as Moderna charts a path forward after the rapid decline in demand for its Covid vaccine. Moderna on ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...